The UK is investing more in its ‘Grand Challenge’ to tackle dementia, with a £40 million investment in a dedicated headquarters for early-stage research.
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS